Is dual immunotherapy needed in first-line treatment of microsatellite instability (MSI)-high metastatic colorectal cancer?

Sukeshi Patel Arora; Saranya Dinesan; Naga K.S. Cheedella; Shruti Pandita

doi:10.21037/apm-22-1426

Is dual immunotherapy needed in first-line treatment of microsatellite instability (MSI)-high metastatic colorectal cancer?

Sukeshi Patel Arora, Saranya Dinesan, Naga K.S. Cheedella, Shruti Pandita

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	427-430
Number of pages	4
Journal	Annals of palliative medicine
Volume	12
Issue number	2
DOIs	https://doi.org/10.21037/apm-22-1426
State	Published - Mar 31 2023

Keywords

Immunotherapy
colorectal cancer (CRC)
ipilimumab
microsatellite instability (MSI)
nivolumab

ASJC Scopus subject areas

Advanced and Specialized Nursing
Anesthesiology and Pain Medicine

Access to Document

10.21037/apm-22-1426

Cite this

@article{85c21abea0334b20bcf8c1dc818f9853,

title = "Is dual immunotherapy needed in first-line treatment of microsatellite instability (MSI)-high metastatic colorectal cancer?",

keywords = "Immunotherapy, colorectal cancer (CRC), ipilimumab, microsatellite instability (MSI), nivolumab",

author = "Arora, {Sukeshi Patel} and Saranya Dinesan and Cheedella, {Naga K.S.} and Shruti Pandita",

year = "2023",

month = mar,

day = "31",

doi = "10.21037/apm-22-1426",

language = "English (US)",

volume = "12",

pages = "427--430",

journal = "Annals of palliative medicine",

issn = "2224-5820",